Chi Yong-Kun, Chen Ying, Li Xiao-Ting, Sun Ying-Shi
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Oncotarget. 2017 Jun 27;8(37):61662-61673. doi: 10.18632/oncotarget.18665. eCollection 2017 Sep 22.
The prognosis of patients with esophageal cancer improves by using neoadjuvant chemotherapy (NAC). More patients obtain pathological N0 staging (pN0) after surgery. The heterogeneity of prognosis of these patients poses a great challenge of customizing therapeutic strategies for individual patients. The signs of lymph nodes on both pre and post NAC computer tomography (CT) scan can provide more information for evaluation. Therefore, we investigated a new approach to lymph node (LN)-survival analysis by using pre-/post-NAC CT in pN0 esophageal cancer. 79 patients undergone curative resection after NAC obtained pN0 staging. The long and short axis diameter of maximal lymph node (MaxLN) and LN number on pre-/post-NAC CT scans were recorded and assessed for predicting survival by univariate and multivariate survival analysis. The prognosis of patients with esophageal cancer was correlated with the LN size and number on pre-/post-NAC CT. The LN number on pre-NAC CT and short-axis diameter of MaxLN on post-NAC CT remained the independent predictor of overall survival. By using these two factors as classification criterion, N0b group included patients with LN number>4 on pre-NAC CT or short-axis diameter of MaxLN >7 mm on post-NAC CT and the rest patients were included in N0a group. N0a group had a significantly better overall survival than N0b group (5-year survival rate: 75.2% vs. 32.6%). The size and number of lymph node on pre-/post-NAC CT were reliable and important prognostic factors in patients with pN0 esophageal cancer. This new criterion could distinguish these patients into N0a and N0b, according to different prognosis.
采用新辅助化疗(NAC)可改善食管癌患者的预后。术后更多患者获得病理N0分期(pN0)。这些患者预后的异质性给为个体患者定制治疗策略带来了巨大挑战。NAC前后计算机断层扫描(CT)上淋巴结的征象可为评估提供更多信息。因此,我们研究了一种通过NAC前后CT对pN0期食管癌进行淋巴结(LN)生存分析的新方法。79例NAC后接受根治性切除的患者获得了pN0分期。记录NAC前后CT扫描上最大淋巴结(MaxLN)的长短轴直径和LN数量,并通过单因素和多因素生存分析评估其对生存的预测价值。食管癌患者的预后与NAC前后CT上的LN大小和数量相关。NAC前CT上的LN数量和NAC后CT上MaxLN的短轴直径仍然是总生存的独立预测因素。以这两个因素作为分类标准,N0b组包括NAC前CT上LN数量>4或NAC后CT上MaxLN短轴直径>7 mm的患者,其余患者纳入N0a组。N0a组的总生存明显优于N0b组(5年生存率:75.2%对32.6%)。NAC前后CT上LN的大小和数量是pN0期食管癌患者可靠且重要的预后因素。这一新标准可根据不同预后将这些患者分为N0a和N0b组。